Frontiers in Immunology · مجلد 16 · 1690464-1690464
Gliomas, and particularly glioblastoma (GBM), remain among the most lethal primary brain tumors, with outcomes constrained by extensive intra tumor heterogeneity, a profoundly immunosuppressive tumor microenvironment (TME), and the restrictive nature of the blood-brain barrier (BBB). Although immunotherapies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T and NK cells, and oncolytic virotherapy, have redefined treatment paradigms in other malignancies, their efficacy in gliomas has been modest, limited by low tumor mutational burden, antigenic plasticity, metabolic suppression, and therapy-associated immunosuppression. Recent advances in multi-antigen targeting, metabolic reprogramming, and innovative delivery strategies have enhanced preclinical efficacy, while the integration of emerging biomarkers such as ADAMTSL4, ACSS3, and radiomics-derived immune signatures offers opportunities for precision patient stratification. Converging developments in real-time molecular monitoring, spatial immunoprofiling, and rationally designed combination regimens hold the potential to recalibrate the glioma immune landscape, paving the way toward clinically impactful and durable immunotherapeutic responses.
Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.
BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.
The molecular axis underlying the epidemiologically established association between periodontitis and coronary heart disease (CHD) remains undefined at mechanistic, systems-level resolution. Classical comparative transcriptomics captures correlational gene lists but cannot reconstruct directional disease-state dynamics or locate the point along a disease-state ordering at which inflammatory resolution fails. ReNODE-Ferro integrates three public bulk transcriptomic datasets (GSE16134, periodontitis, n = 310; GSE28829, CHD staged, n = 29; GSE100927, CHD plaque, n = 104) through a nine-module biologically curated feature space (123 genes), a fully connected latent encoder, a Neural Ordinary Differential Equation (latent dim = 12) learning continuous disease-state dynamics across six biologically defined states (S0–S5), and a model-based reinforcement learning (RL) controller identifying optimal biological intervention policies in latent space. Twenty-four genes were concordantly dysregulated (FDR < 0.05) across all three datasets. Cross-disease fold-change concordance was significant (Spearman r = 0.473, p = 3.29 × 10 − 8, periodontitis vs. CHD staged). Ferroptotic vulnerability and coronary coupling co-varied with r = 0.830 ( p = 3.89 × 10 − 114). Neural ODE tipping-point analysis identified the S2→S3 metabolic strain-to-ferroptosis-primed transition as the transition carrying the highest modelled velocity, although under a held-out validation scheme the velocity profile proved comparatively flat and the location of the maximum unstable across bootstrap refits. S2 was the least responsive state to single-step intervention (3.7%), but it contains only six specimens and was the least stable cluster on resampling. RL policy optimization identified antioxidant restoration, mitochondrial quality enhancement, and pro-resolution amplification as the universal intervention triad (mean reward improvement = 0.583). Robustness analyses added at revision support and delimit these findings. Tissue of origin explained no measurable variance in the nine-module space (PERMANOVA R² < 0.001, p = 1.00) whereas disease status explained 14.0% ( p < 1 × 10⁻⁴), and the ferroptotic vulnerability–coronary coupling association persisted after adjustment for estimated cellular composition (ρ = 0.764) and within every cohort analysed separately (ρ = 0.77–0.89). An independent diffusion-pseudotime ordering reproduced the state sequence (ρ = 0.872) and placed S2 before S3 ( p = 2.4 × 10⁻¹⁰), and leave-one-cohort-out re-derivation recovered the same structure in all three folds. Against 5,000 size-matched random gene panels the curated feature space was strongly informative (empirical p = 2.0 × 10⁻⁴), although an uncurated transcriptome-wide analysis showed the ferroptotic axis to be one of several concordant programmes rather than a uniquely dominant one. Periodontitis and coronary atherogenesis share a conserved ferroptotic-metabolic resolution failure trajectory. ReNODE-Ferro provides a mechanistically grounded, interventionally actionable map of this continuum, establishing ferroptotic vulnerability as a principal and unusually tightly coupled molecular axis of this shared programme. Because all three cohorts are cross-sectional, the reconstructed trajectory is a statistical ordering rather than a demonstrated temporal or causal sequence.
Ubiquitin machinery is an essential regulatory system that maintains protein stability, degradation, and signalling by balancing ubiquitination and deubiquitination. In addition to its classical function in protein tagging for proteasomal degradation, ubiquitin has several essential cellular functions, including cell-cycle regulation, DNA repair, immunomodulation, intracellular signalling, and cellular stress responses. Abnormal regulation of this highly ordered system has been implicated in the pathogenesis of cancer, neurodegenerative diseases, infectious diseases, metabolic dysfunction, and autoimmunity. Recent developments in structural biology, chemical biology, and proteomics have increased our understanding of ubiquitin signalling and identified new therapeutic targets by revealing context-specific interactions within nodes of the ubiquitinproteasome system. Future approaches to restore proteostasis involve selective inactivation of proteasomal subunits, E3 ligases, and deubiquitinating enzymes (DUBs), as well as novel modalities such as proteolysistargeting chimeras (PROTACs) and molecular glues that redirect ubiquitin-dependent degradation of diseaserelevant proteins. Although preclinical and early clinical studies have demonstrated target specificity, longterm safety remains a challenge for clinical translation. This review provides an overview of ubiquitin's pathophysiological functions in key human diseases, therapeutic interventions, and the potential of ubiquitin-based therapeutic strategies for precision medicine and targeted drug therapy.
Journal of Agricultural and Food Chemistry · مجلد 73 (21) · 12747-12764
Jojoba ( Simmondsia chinensis ) seeds are broadly used worldwide for their valuable oil. The chemical composition of the other parts of the jojoba shrub remains largely unexplored. In this work, the metabolite profiles of aqueous and methanolic extracts from different jojoba plant organs were analyzed by liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (LC-QTOF-MS/MS) combined with molecular networking (MN), resulting in the assignment of 104 metabolites from different classes. All methanolic extracts evinced significant antibacterial activity against the examined bacterial strains. Subminimum inhibitory concentrations (sub-MICs) of the hull and leaf extracts successfully inhibited biofilm formation of Staphylococcus aureus with inhibition rates above 90%. The seed extract at 0.5 MIC effectively eradicated S. aureus and Enterococcus faecalis biofilms (>80%). Multivariate data analysis revealed the positively correlated biomarkers with bioactivity, primarily flavonoids, phenolic compounds, and simmondsins. These results present a ground for future research to valorize jojoba seed-derived products and byproducts from other organs.
ClinicoEconomics and Outcomes Research · مجلد Volume 17 · 217-232
Background and Objectives: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is a promising disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS). This study investigates its cost-effectiveness compared to teriflunomide from the perspective of Saudi healthcare payers. This comparison is crucial for informing treatment strategies and resource allocation in Saudi Arabia, where RRMS poses a significant healthcare burden and access to newer DMTs is evolving. Patients and Methods: A Markov model was constructed to evaluate the long-term cost-effectiveness of ofatumumab compared to teriflunomide for treating RRMS in Saudi Arabia. This model simulates disease progression over 10 years, a timeframe chosen for its clinical relevance and consistency with similar studies. To reflect the Saudi patient population, the model uses a hypothetical cohort with characteristics mirroring those in the ASCLEPIOS I/II clinical trials. The model incorporates transition probabilities between disease states, primarily derived from the British Columbia MS (BCMS) database and further refined using data from the ASCLEPIOS trials. To ensure relevance to the Saudi context, local data sources were utilized, including drug costs from the Saudi Food and Drug Authority (SFDA) and health state costs from published local studies. Clinical expert input was incorporated to validate model assumptions.The primary outcome measure was the incremental cost per quality-adjusted life-year (QALY) gained. Sensitivity analyses were conducted to assess the robustness of the model findings. Results: Compared to teriflunomide, ofatumumab yielded incremental cost-effectiveness ratios (ICERs) of $46,188 per QALY over the 10-year period. Ofatumumab demonstrated a greater impact on reducing disability progression, particularly in the early stages of the disease. At a willingness-to-pay (WTP) threshold of $99,120 per QALY, ofatumumab demonstrated a 99.14% probability of cost-effectiveness in probabilistic sensitivity analyses. Conclusion: This cost-effectiveness analysis demonstrates that ofatumumab is a cost-effective treatment for RRMS in Saudi Arabia, with an ICER below the WTP. Policymakers should consider including ofatumumab in national formularies and prioritize its use in early-stage RRMS to maximize patient benefit and cost-effectiveness.
Journal of Advanced Trends in Medical Research · مجلد 2 (3) · 596-601
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of chronic liver diseases. Inconsistency in the microbiome population of individual guts and host–microbial interactions leads to low response in dietary and pharmacological-based treatments. This study aimed to develop and evaluate a metagenomic-guided, culturally adapted dietary and probiotic intervention to reduce hepatic fat and improve metabolic outcomes in obese Saudi adults with NAFLD. Materials and Methods: We combined gut metagenomic analysis, machine learning-based diet modelling and tailored probiotic supplementation to create an intervention platform. Probiotic specificity depends on functional deficits in bacteria participating in specific metabolic pathways, particularly bile acid metabolism. This technique supplements medication with microbiome-based drug processing. Results: At week 24, magnetic resonance imaging–proton density fat fraction (MRI-PDFF) decreased by −3.4 ± 2.2% (control), −8.9 ± 3.1% (diet) and −12.3 ± 3.8% (diet + probiotics); liver fat reduction was significant (analysis of variance (ANOVA) P = 0.0004). In the combined intervention, Faecalibacterium prausnitzii increased 2.3-fold (P = 0.003), faecal butyrate rose from 28.7 ± 4.1 to 45.2 ± 5.6 μmol/g (P = 0.002), faecal deoxycholic acid (fDCA) fell 34% (P = 0.010) with a rise in ursodeoxycholic acid (UDCA) (P = 0.015) and high-sensitivity C-reactive protein declined 42% (6.4 ± 1.7 to 3.7 ± 1.3 mg/L) versus 18% in controls (between-group P = 0.0008). Conclusion: Our precision-guided approach is a novel, scalable solution to managing NAFLD, leveraging the alignment of interactions between hosts, the microbiome and diet within a cultural context. The framework has the potential to optimise therapeutic response in high-risk Saudi communities, and the individual modulation of microbiomes on metabolic diseases is highlighted.
International Journal of Surgery · مجلد 112 (2) · 4563-4574
BACKGROUND: Cancer poses a persistent global health challenge, and one of its most formidable characteristics is the ability to evade immune detection. Understanding these immune evasion mechanisms is essential for improving therapeutic outcomes, especially in the era of personalized medicine. Recent advances in single-cell multiomics technologies have opened new avenues for exploring tumor-immune interactions at unprecedented resolution. OBJECTIVE: This review aims to critically examine how single-cell multiomics platforms, integrating genomics, transcriptomics, epigenomics, and proteomics, have been applied to identify immune evasion mechanisms in cancer and how these findings contribute to the development of precision oncology. METHODS: A structured literature search was conducted in PubMed, Scopus, and Web of Science, focusing on studies published between 2018 and 2025. Relevant research articles employing single-cell multiomics in the context of cancer immune evasion were selected, analyzed, and thematically organized according to the type of omics technology used and clinical relevance. RESULTS: The findings highlight that single-cell multiomics enables the detection of rare immune-resistant cellular subtypes, the identification of altered immunoregulatory pathways, and the characterization of epigenetic reprogramming events involved in immune escape. This integrative approach reveals dynamic and context-dependent mechanisms by which tumors adapt and resist immunotherapy. CONCLUSIONS: Single-cell multiomics technologies provide a comprehensive and nuanced understanding of cancer immune evasion. These insights not only explain failures in current immunotherapy strategies but also inform the development of more effective and personalized treatment interventions. The integration of these platforms into clinical research represents a significant step toward overcoming immune resistance in oncology.
Drug Development Research · مجلد 86 (5) · e70131-e70131
Since lung cancer accounts for approximately 20% of cancer-related fatalities globally, it is one of the most common and deadly cancers, necessitating the discovery of innovative, potent, and less toxic treatment agents as imperative. Opportunistically, phytoflavonoids (PFs), a specific class of phytochemicals, display promising anticancer activity through their multimodal apoptosis-inducing properties. Based on existing evidence, the present study employs an integrative multi-omics approach to assess the target-specific binding efficacy and drug-ability outlines of PFs against lung cancer. We selected two of the most likely lung cancer targets using the core part of PFs: carbonic anhydrase IX (PDB ID: 3DAZ) and poly(A) binding protein cytoplasmic 1 (PDB ID: 3KUJ). Another two key targets, glutathione S-transferase P1 (PDB ID: 3GSS) and 17β-hydroxysteroid dehydrogenase 1 (HSD17B1, 3HB4), were also included in our study based on recent literature. The potency of 66 PFs against four targets was assessed through a molecular docking study using PyRx 0.8-AutoDock 4.2 software. PF15, PF43, PF6, and PF26 were the lead candidates. Further, physicochemical profiles through standard Lipinski rule of five parameters and toxicity and drug-ability profiles suggested that PF43 (naringenin) is the most ideal lead candidate among them. Molecular dynamics (MD) simulation studies were performed at 200 ns to observe the kinetic behaviors of CA9-PF43 and CA9-U-1014 docking complexes along with the calculated free energy through the MM/PBSA method. From both analyses, PF43 showed higher stability and lower free energy, expressing its potency over the standard drug. We also investigated the structure-activity relationship and frontier molecular orbitals to highlight the drug chemistry of lead PFs. The integrative multi-omics investigation suggested that using PF43 for lung cancer treatment could increase the chances of experimental success. Overall, the systematic computational analyses provide a platform for lead identification and pave the way for precision phytotherapy in current drug discovery.
lung cancerflavonoidsnaringenincarbonic anhydrase IX
Journal of Advanced Trends in Medical Research · مجلد 2 (1) · 69-75
Abstract Background: Preoperative immunonutrition is a promising approach to enhance surgical outcomes in high-risk populations, such as pediatric patients with chronic kidney disease (CKD). However, conventional protocols often fail to account for individual biological variability, limiting their effectiveness. Objectives: To develop a precision-based immunonutrition framework that integrates multi-omic data to predict individual responses and tailor nutritional interventions in pediatric CKD patients undergoing surgery. Methods: Our approach combines gut microbiome composition, host gene expression, and metabolic profiles using canonical correlation analysis (CCA) to extract latent multi-omic interactions. These features are then used to train a random forest classifier that predicts immunonutrition responsiveness with probabilistic scoring. The system dynamically adjusts interventions, including arginine and omega-3 fatty acid supplementation, based on predicted response levels. The framework leverages high-throughput sequencing, metabolomics, and scalable computing for real-time clinical integration. Results: The proposed system successfully predicted patient-specific responses to immunonutrition and supported personalized adjustments. It integrates smoothly with standard dietitian workflows and enhances clinical decision-making through data-driven insights. In pediatric CKD contexts, this approach demonstrated a marked potential for reducing post-operative complications. Conclusion: By shifting from a generalized to a precision-based paradigm, this framework lays the groundwork for individualized immunonutrition strategies in vulnerable pediatric populations. The model offers clinical scalability and may significantly improve surgical outcomes, particularly in personalized care settings like Saudi Arabia.
Journal of Advanced Trends in Medical Research · مجلد 2 (3) · 523-528
Background: Diabetic neuropathy is a common and disabling complication of type 2 diabetes (T2D), often linked to Vitamin B12 deficiency. Despite observed B12 malabsorption in T2D patients, the role of gut microbiota in this process is poorly understood. Methods: We established a novel fecal microbiota transplantation (FMT) model using samples from T2D patients stratified by B12 status and neuropathy severity, transplanted into germ-free mice. We assessed ileal expression of B12 transporters, serum B12 levels and cobalamin-related metabolites. Neuropathy progression was evaluated through nerve conduction studies and histopathological analysis. Microbial composition was analysed through 16S rRNA sequencing, and metabolomic data were obtained using ion mobility-enhanced liquid chromatography-mass spectrometry. Machine learning algorithms integrated microbial and host data to identify predictive patterns and therapeutic targets. Results: FMT from T2D donors with B12 deficiency led to decreased expression of B12 absorption markers and reduced serum B12 levels in recipient mice. These mice showed early signs of neuropathy, confirmed by slowed nerve conduction and structural nerve damage. Specific microbial taxa were significantly associated with altered B12 metabolism and indicators of neuropathy. Multiomics and machine learning analyses revealed key microbial signatures and metabolic pathways involved in B12 dysregulation. Conclusion: Gut microbiota plays a mechanistic role in Vitamin B12 malabsorption and the progression of diabetic neuropathy. This model provides a platform for microbiota-informed diagnostics and targeted interventions in T2D complications.
Journal of Advanced Trends in Medical Research · مجلد 2 (3) · 620-628
Background: Precision oncology in advanced urologic malignancies frequently uses genomic markers, which are insufficient to fully represent tumour metabolic heterogeneity. This study investigated if integrative lipidomics – metabolomics profiling by surface-assisted laser desorption/ionisation mass spectrometry (SALDI-MS) and a supervised machine-learning pipeline could be leveraged to enable informed decision-making for targeted therapy selection. Methods: SALDI-MS was completed on resected or biopsy tumour material with concomitant Liquid Chromatography-mass spectrometry (MS)/MS-based annotations of lipids/metabolites. Features were harmonised and modelled with a hybrid graph neural network – Transformer classifier, using nested cross-validation as well as Delong tests for area under the curve comparison. A blinded retrospective cohort with matched clinical treatment decisions was used for evaluations. Results: Compared with matrix-assisted laser desorption/ionisation MS, nanostructured Si@Au SALDI-MS substrates enhanced the number of detected lipid/metabolite features by 47% from tissue sections. The integrative model found 37 high-parameter lipid – metabolite features, and enhanced discrimination compared with single dimensional models by 11%–18% ( P < 0.001). In a blinded cohort of 87 patients, the therapy-selection model performed with 79% accuracy compared with 48% for programmed death-ligand 1 immunohistochemistry alone; the mean area under the receiver operating characteristic in the ablation analyses was 0.91 ± 0.03. Conclusions: Integrative SALDI-MS lipidomics – metabolomics, together with machine learning, demonstrated promise to inform targeted therapy decisions in advanced urologic cancers, and deserves prospective validation.
Advances in computational intelligence and robotics book series · 363-376
This chapter provides an overview of the history and impact of artificial intelligence on businesses, with a specific focus on the pharmaceutical industry and research. It discusses the basic principles of pharmacoeconomics, explores ways AI can enhance business processes, and examines various applications of AI in pharmaceutical research, such as drug development, digital therapy, personalized treatment, clinical trials, epidemic forecasting, and supply chain management. The chapter also addresses challenges and considerations related to ethics, safety, data privacy, and liability in AI implementation. Finally, the discussion provides insights into AI's economic opportunities and implications in pharmaceutical research.
artificial intelligencepharmaceutical industrypharmacoeconomicsdrug development